VivoPower PLC Overview
Industry: None
Sector: None
Read MoreMavefund brings filings, fundamentals, valuation, price history and news for VivoPower PLC into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Exhibit 99.1 VivoPower Secures US$50 Million PIPE At US$7.50 Conversion Price Per Share Blue Sky Capital, a New York based specialist AI data center institutional investor and the first institutional investor in Nscale, led this strategic investment round Arc...
What changed
- Review the SEC source filing for the full reported results and management commentary.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
SEC filing
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
Headline from Yahoo Finance: RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias.
Olio Labs releases study showcasing AI-driven in vivo platform can predict clinical trial outcomes
Headline from Morningstar: Olio Labs releases study showcasing AI-driven in vivo platform can predict clinical trial outcomes.
Amdocs renews managed services deal with Vivo in Brazil
Headline from Investing.com: Amdocs renews managed services deal with Vivo in Brazil.
Amdocs renews managed services deal with Vivo in Brazil By Investing.com
Headline from Investing.com India: Amdocs renews managed services deal with Vivo in Brazil By Investing.com.
Amdocs renews managed services deal with Vivo in Brazil By Investing.com
Headline from Investing.com Canada: Amdocs renews managed services deal with Vivo in Brazil By Investing.com.
Olio Labs releases study showcasing AI-driven in vivo platform can predict clinical trial outcomes
Headline from Yahoo Finance: Olio Labs releases study showcasing AI-driven in vivo platform can predict clinical trial outcomes.
Earnings Per Share
Score 0/5
VivoPower PLC Financial ratio data is updating.
Return on Equity
Score 0/5
VivoPower PLC Financial ratio data is updating.
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0/5
VivoPower PLC
Financial ratio data is updating.
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 0/5
VivoPower PLC
F
i
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios